We’re excited to announce that Biocytogen will attend ASGCT 2026 in Boston, MA from May 11th-15th. As the largest cell and gene therapy event, this conference offers insights into the latest developments in the field. Come meet our team at the booth #1415 to grab some swag and learn more about what Biocytogen has to offer!
What is the ASGCT 2026?
The American Society of Gene and Cell Therapy (ASGCT) is a global organization of professionals in the cell and gene therapy field. Their annual meeting serves as a platform for scientific exchange and exploration of new technologies. This is a great opportunity to stay up to date with the latest developments and form meaningful connections with top industry leaders.
Event Overview
Date: May 11th - 15th, 2026
Venue: Thomas M. Menino Convention & Exhibition Center, 415 Summer St, Boston, MA 02210
Event Schedule
For more information, please refer to the event program.
About BIOCYTOGEN
Biocytogen (SSE: 688796; HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen leverages genetically engineered proprietary RenMice® platforms for fully human monoclonal/bispecific/multispecific antibody discovery, bispecific antibody-drug conjugate discovery, nanobody discovery and TCR mimic antibody discovery, and has established a sub-brand, RenBiologics™, to explore global partnerships for an off-the-shelf library of >1,000,000 fully human antibody sequences against over 1000 targets for worldwide collaboration. As of June 30, 2025, approximately 280 therapeutic antibody and multiple clinical asset co-development/out-licensing/transfer agreements and over 50 target-nominated RenMice® licensing projects have been established around the globe, including several partnerships with multinational pharmaceutical companies (MNCs). Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides a few thousand off-the-shelf animal and cell models under the company's sub-brand, BioMice™, along with preclinical pharmacology and gene-editing services for clients worldwide. Headquartered in Beijing, Biocytogen has branches in China (Haimen Jiangsu, Shanghai), USA (Boston, San Francisco, San Diego), and Germany (Heidelberg). For more information, please visit https://biocytogen.com.
Let’s shape the future of cell and gene therapy together, we look forward to meeting you in Boston, MA!
